Volnay Therapeutics is a biotechnology company focused on accelerating the development of novel gene and cell therapies. With a team experienced in drug development, Volnay identifies promising therapeutic assets and innovative enabling technologies, providing funding and operational support to advance these initiatives. The company aims to create value for investors and patients by prioritizing capital efficiency, economic viability, and manufacturing innovation.
March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. Its primary focus is on developing CAR-T cell therapies, with a lead asset, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia, currently in Phase 1 trials. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process that prioritizes cell functionality and consistency.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.